酶联免疫斑点法检测鼻咽癌患者放疗前后T细胞对EB病毒肽段的特异性反应  

ELISPOT Assay to Detect Specific Reaction of T Cells to EBV Peptide Segments for Patients with Nasopharyngeal Carcinoma before and after Radiotherapy

作　　者：王若峥[1] 谭遥[1] 王多明[1] 黄莉[1] 李晓霞[1] 

机构地区：[1]新疆医科大学附属肿瘤医院放一科,乌鲁木齐830011

出　　处：《肿瘤防治研究》2009年第11期928-931,共4页Cancer Research on Prevention and Treatment

摘　　要：目的用酶联免疫斑点法(ELISPOT法)检测鼻咽癌患者放射治疗前后免疫反应性的变化,寻找与疗效相关的细胞免疫反应指标。方法选择新疆医科大学附属肿瘤医院2007年6月～2008年12月由病理确诊的鼻咽癌初治患者41例,用ELISPOT法检测放射治疗前及治疗后3月患者外周血中CTL细胞对LMP1、LMP2、EBNA1和EBNA3多肽反应性的差异,并分析其与近期疗效的关联性。结果放射治疗后CR36例,PR4例,PD1例;放射治疗后3月,外周血中对LMP1抗原多肽产生特异性反应的CTL细胞频数显著增加(P=0.004),对LMP2、EBNA1和EBNA3多肽反应性无统计学意义。不同疗效组之间放射治疗前后对LMP1抗原多肽产生特异性反应的CTL细胞频数差异有统计学意义。结论鼻咽癌患者放射治疗前及放射治疗后3月,应用ELISPOT法,检测外周血LMP1抗原相关多肽的变化可能有助于临床疗效的判定,为今后个体化免疫治疗方案的实施提供实验室依据。Objective To investigate the change of specific immunoreaction of T cells before and after radiotherapy in the patients with nasopharyngeal carcinoma,and to search the factors correlated to the curative effect.Methods Forty-one nasopharyngeal carcinoma patients were investigated in the study.10 ml blood were taken before and 3 months after the radiotherapy, PBMCs were separated and specific responses T cell to EBV peptide segments such as eptide,LMP1,LMP2,EBNA1 and EBNA3 were measured by using ELISPOT assay. Results We found that,after radiotherapy,there are 36 cases of CR,4 cases of PR,1 case of PD,whose frequency of CTL cells in peripheral blood response to LMP1 significantly increased（P=0.004）,while had no statistical significance in the respone to LMP2 、EBNA1 and EBNA3.The frequency of CTL cells in the groups with different curative effect responsed to LMP1 also had statistical significance.Conclusion ELISPOT assay can be used to detect the specific responses of T cell to LMP1 before and after radiotherapy in the patients with nasopharyngeal carcinoma.This provides basic data for the development of potential therapy in combination of immunoand radiotherapy,as well as for the evaluation of the treatment to these patients.

关 键 词：鼻咽癌 放射治疗 酶联免疫斑点法 

分 类 号：R739.63[医药卫生—肿瘤]